MX2007010659A - Regimenes de dosificacion para trans-clomifeno. - Google Patents

Regimenes de dosificacion para trans-clomifeno.

Info

Publication number
MX2007010659A
MX2007010659A MX2007010659A MX2007010659A MX2007010659A MX 2007010659 A MX2007010659 A MX 2007010659A MX 2007010659 A MX2007010659 A MX 2007010659A MX 2007010659 A MX2007010659 A MX 2007010659A MX 2007010659 A MX2007010659 A MX 2007010659A
Authority
MX
Mexico
Prior art keywords
reduction
clomiphene
trans
dosing regimes
hypogonadism
Prior art date
Application number
MX2007010659A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of MX2007010659A publication Critical patent/MX2007010659A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007010659A 2005-03-22 2006-03-17 Regimenes de dosificacion para trans-clomifeno. MX2007010659A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66429005P 2005-03-22 2005-03-22
PCT/US2006/010022 WO2006102232A2 (en) 2005-03-22 2006-03-17 Dosing regimes for trans-clomiphene

Publications (1)

Publication Number Publication Date
MX2007010659A true MX2007010659A (es) 2007-11-08

Family

ID=37024477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010659A MX2007010659A (es) 2005-03-22 2006-03-17 Regimenes de dosificacion para trans-clomifeno.

Country Status (14)

Country Link
US (2) US8247456B2 (enExample)
EP (2) EP1865938A4 (enExample)
JP (3) JP5785680B2 (enExample)
KR (1) KR20070114187A (enExample)
CN (1) CN101163467B (enExample)
AU (1) AU2006227243B2 (enExample)
BR (1) BRPI0609389A2 (enExample)
CA (2) CA2597700A1 (enExample)
MX (1) MX2007010659A (enExample)
NZ (1) NZ560551A (enExample)
PL (1) PL383444A1 (enExample)
RU (1) RU2413508C2 (enExample)
WO (1) WO2006102232A2 (enExample)
ZA (1) ZA200707774B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289075C (zh) 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
NZ560551A (en) 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
BRPI0717756B1 (pt) 2006-10-31 2018-01-30 Basf Se Processo para a produção de partículas poliméricas absorventes de água
MX2010004195A (es) * 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
TWI458478B (zh) * 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
UA113291C2 (xx) * 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013020215A1 (en) * 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
AU2013221478B2 (en) * 2012-02-14 2017-06-01 Repros Therapeutics Inc. Selective estrogen receptor modulators with short half-lives and uses thereof
MX2014009322A (es) * 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
CA2872644A1 (en) 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
CN104994877A (zh) * 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
HK1223318A1 (zh) * 2013-06-05 2017-07-28 Repros Therapeutics Inc. 作爲提高骨矿物质密度的药剂的反式克罗米芬和它的类似物
JP2019506425A (ja) * 2016-02-25 2019-03-07 アスペン パーク ファーマシューティカルズ，インコーポレイティド クロミフェン異性体の経口剤形および続発性性腺機能低下症を治療するために経口剤形を使用する方法
CN108463453A (zh) 2016-04-22 2018-08-28 意大利合成制造有限公司 用于制备具有针状晶体习性的柠檬酸恩氯米芬的方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061733A (en) * 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) * 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
WO1995035093A1 (en) 1994-06-17 1995-12-28 University Of Nebraska Board Of Regents In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
CA2228610C (en) 1995-08-17 2008-06-03 Heidi Rolfes Controlled release products
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
ATE277739T1 (de) * 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
JP4496316B2 (ja) * 1997-04-03 2010-07-07 エーザイ インコーポレイテッド 生分解性テレフタレートポリエステル−ポリホスフェートポリマー、組成物、物品、並びにその製造及び使用方法
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
RU2200732C2 (ru) * 1997-08-12 2003-03-20 Глэксо Вэллкам Инк. Производные трифенилэтилена, способы лечения и профилактики остеопороза, рака груди и сердечно-сосудистого заболевания
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
NZ510201A (en) 1998-07-30 2002-10-25 Stoller Ets Treatment of plants with salicylic acid and organic amines
DE69935335T2 (de) * 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP5184727B2 (ja) * 1999-06-11 2013-04-17 ワトソン ファーマシューティカルズ， インコーポレイテッド 女性への非経口アンドロゲンステロイドの投与
CA2321321A1 (en) * 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) * 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
WO2001091744A1 (en) * 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
ATE278421T1 (de) * 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6743448B2 (en) * 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US6872986B2 (en) * 2001-07-04 2005-03-29 Nichia Corporation Nitride semiconductor device
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
CN1289075C (zh) * 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1429779A2 (en) * 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) * 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
JP4312522B2 (ja) 2003-06-30 2009-08-12 株式会社リコー 現像剤補給方法、現像剤補給装置、及び、画像形成装置
EP1776098A1 (en) 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
WO2006084153A2 (en) * 2005-02-04 2006-08-10 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
EP1853298A2 (en) * 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
NZ560551A (en) 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
US20080306035A1 (en) 2005-08-05 2008-12-11 Repros Therapeutics Inc. Methods and Compositions for Treating Female Infertility Using Clomiphene
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.

Also Published As

Publication number Publication date
EP2392322A2 (en) 2011-12-07
RU2413508C2 (ru) 2011-03-10
CN101163467B (zh) 2012-07-18
AU2006227243B2 (en) 2011-10-27
HK1119070A1 (en) 2009-02-27
KR20070114187A (ko) 2007-11-29
EP2392322A3 (en) 2012-02-22
BRPI0609389A2 (pt) 2010-03-30
JP2008534503A (ja) 2008-08-28
JP6270281B2 (ja) 2018-01-31
US8519004B2 (en) 2013-08-27
JP2015044867A (ja) 2015-03-12
RU2007138867A (ru) 2009-04-27
ZA200707774B (en) 2009-09-30
CA2597700A1 (en) 2006-09-28
WO2006102232A2 (en) 2006-09-28
CN101163467A (zh) 2008-04-16
EP1865938A2 (en) 2007-12-19
US20120309839A1 (en) 2012-12-06
CA3071412A1 (en) 2006-09-28
US20090215907A1 (en) 2009-08-27
PL383444A1 (pl) 2008-03-17
JP2018024712A (ja) 2018-02-15
US8247456B2 (en) 2012-08-21
AU2006227243A1 (en) 2006-09-28
WO2006102232A3 (en) 2007-04-12
EP1865938A4 (en) 2008-09-24
JP5785680B2 (ja) 2015-09-30
NZ560551A (en) 2010-02-26

Similar Documents

Publication Publication Date Title
WO2006102232A3 (en) Dosing regimes for trans-clomiphene
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
IL258880A (en) Diarylhydantoin compounds
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
UA84930C2 (ru) Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2008046083A3 (en) Use of oxindole compounds as therapeutic agents
SG170809A1 (en) Diarylthiohydantoin compounds
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
UA93004C2 (ru) Композиция для вагинального применения
WO2006083970A3 (en) Tumor necrosis factor inhibitors
TW200724140A (en) Hydantoin compounds
TW200716088A (en) Formulations and methods for treating amyloidosis

Legal Events

Date Code Title Description
FG Grant or registration